- Sales growth was 27 percent in local currency. Sales amounted to SEK 105 (86) million, corresponding to an increase of 22 percent in SEK.
- Operating income (EBIT) amounted to SEK 17 (10) million, corresponding to an operating margin of 16 (12) percent.
- Net income amounted to SEK 12 (7) million, which gave earnings per share of SEK 0.61 (0.38).
After the end of the period
- During 2010 Vitrolife entered into a collaboration agreement with the Danish company HertArt ApS with a view to developing a new range of disposable plastic products for IVF under the name of Labware. Vitrolife acquired 25 percent of the shares in HertArt as part of the collaboration agreement. On April 1, 2013 Vitrolife exercised an option to acquire all the shares in the company.
Gothenburg, April 19, 2013
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 19, 2013 at 08:30 a.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.